Jo-Ann Latkowski, MD, New York University School of Medicine, New York, New York; Peter Heald, MD, Yale University School of Medicine, New Haven, Connecticut

Abstract
In this article, the management of cutaneous T-cell lymphoma will be presented in terms of the strategies that guide treatment. With the strategies and goals in mind, treatment options to achieve a measurable goal will be presented. The treatments presented in this article are those utilized to reliably achieve a remission. If remission is not achieved, a patient’s management plan must be changed. The landmarks that help guide the therapy plan will be discussed.

(J Clin Aesthetic Dermatol. 2009;2(6):22–27.) Read the rest of this article »

Heather Woolery-Lloyd, MD, Whitney Valins, BS
University of Miami, Department of Dermatology and Cutaneous Surgery, Miami Beach, Florida

Dr. Woolery-Lloyd is a consultant to Valeo Pharma. Ms. Valins reports no conflicts of interest.

Abstract
Hyperhidrosis is a common dermatological condition that has a tremendous impact on the quality of life of affected patients. Aluminum chloride hexahydrate is considered first-line therapy for patients with mild-to-moderate hyperhidrosis. This treatment has been proven to be effective in the treatment of hyperhidrosis; however, its use has been limited by significant irritation. In many patients, the irritant dermatitis is so severe that, despite clinical efficacy, this therapy must be discontinued. There are many topical aluminum chloride therapies available. Observations from a busy hyperhidrosis practice revealed decreased irritation and increased efficacy with a novel therapy that combines 15% aluminum chloride hexahydrate with 2% salicylic acid in a gel base. This combination of 15% aluminum chloride hexahydrate with 2% salicylic acid offers patients who have failed aluminum chloride hexahydrate in the past excellent efficacy with minimal irritation. We report seven cases of patients with a history of severe irritation from aluminum chloride who maintained excellent results with this new topical without any significant irritation.

(J Clin Aesthetic Dermatol. 2009;2(6):28–31.) Read the rest of this article »

Cherie M. Ditre, MD, Assistant Professor of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Editorial support for this article was provided by  the editorial staff at Embryon. This article was funded by Dermik  Laboratories, a business of sanofi-aventis U.S. The author gratefully  acknowledges Patricia Bichler, PhD, who assisted in the preparation of this  article based on author-provided comments. The opinions expressed in the  current article are those of the author. The author received no honoraria  or other form of financial support related to the development of this  manuscript.

Read the rest of this article »

Resident’s Forum

Section Editor: Jerry Tan, MD, FRCPC: Adjunct Professor, University of Western Ontario, London, Ontario; President, Windsor Clinical Research Inc., Windsor, Ontario; and Consultant, Windsor Regional Hospital, Windsor, Ontario, Canada. He is also in private practice.

Resident Section Editors: Sanjay Bhambri, DO, and Joshua Zeichner, MD Read the rest of this article »

Clinical Contact Dermatitis
Section Editor: Matthew J. Zirwas, MD

Matthew J. Zirwas, MD, Matthew A. Molenda, MD

Dr. Matthew J. Zirwas is Assistant Professor of Dermatology, The Ohio State University. Dr.  Molenda is a Dermatology Resident, The Ohio State University, Columbus, Ohio. The authors report no relevant conflicts of interest. Read the rest of this article »